TelyRx Announces Third Quarter 2026 Financial Results

Revenue doubled, but losses and cash burn accelerated despite recurring customer growth.

What the company is saying

TelyRx Holdings Inc. reports Q3 2026 revenue of $23.1 million, up 88% from $12.3 million in Q3 2025, emphasizing rapid top-line growth. The company highlights a 17% increase in revenue per visitor following the launch of its new brand and website, and notes that its formulary now covers over 500 medications. Management, led by President and CEO Vanessa Slowey, stresses that recurring customer revenue reached $17.4 million (up 12% from last quarter), making up three-quarters of total revenue, and frames this as evidence of strengthening business fundamentals. The narrative positions the expansion of operations in Clearwater, Florida—which is claimed to more than triple capacity—as a key step in scaling efficiently, though no baseline or projected capacity numbers are provided. The company acknowledges that operating losses widened, attributing this primarily to $1.0 million in non-cash stock-based compensation, increased advertising and marketing spend, and higher infrastructure and personnel costs to support growth. The tone is confident and growth-focused, but operational and financial risks are downplayed relative to the upbeat messaging.

What the data suggests

The financials show Q3 2026 revenue at $23.1 million, up from $12.3 million a year earlier, with gross profit rising to $13.8 million (60% margin) from $6.9 million (56%). Recurring customer revenue was $17.4 million, up 12% sequentially, while new customer revenue was $5.7 million. Despite these gains, net loss from operations increased to $2.7 million from $0.9 million, and adjusted EBITDA loss widened to $1.3 million from $0.4 million. Free cash flow for the nine months ended September 30, 2026, was negative $9.36 million, compared to negative $1.45 million in the prior year period, reflecting a sharp increase in cash burn and capital expenditures. Cash and cash equivalents, including $10.2 million in restricted cash, stood at $18.7 million at quarter-end. The company attributes higher losses to stock-based compensation, marketing, and infrastructure investments, but does not break out these costs in detail. The 17% improvement in revenue per visitor is a positive operational metric, but the impact of the Clearwater expansion is not quantified. Overall, the data shows strong revenue momentum but deteriorating profitability and liquidity.

Analysis

The announcement presents strong revenue growth (88% YoY) and improvements in gross profit margin, both supported by disclosed figures. However, losses from operations and adjusted EBITDA losses have also increased, and free cash flow is substantially negative, indicating that profitability is deteriorating despite top-line growth. The tone is upbeat, highlighting operational expansion (Clearwater) and brand initiatives, but the claim that capacity will 'more than triple' lacks supporting numerical detail. The expansion and increased spending on marketing and infrastructure signal high capital intensity, with benefits from these investments not yet realised. Most claims are realised and supported by data, but the narrative inflates the significance of operational expansion without quantifying its impact or timeline for profitability. The gap between narrative and evidence is moderate: while growth is real, the path to sustainable profitability remains unproven.

Risk flags

• ●Sustained and increasing operating losses pose a risk to long-term viability, with net loss from operations rising to $2.7 million and free cash flow negative $9.36 million for the nine months, indicating the company is not yet on a path to profitability.
• ●High capital intensity is evident from increased marketing, infrastructure, and personnel spending, as well as a significant jump in capital expenditures, which could pressure liquidity if revenue growth slows or fails to translate into positive cash flow.
• ●The claimed tripling of Clearwater capacity is not supported by baseline or projected capacity figures, making it difficult to assess the scale or timing of operational leverage and whether this expansion will drive profitability or further losses.
• ●A large portion of cash is restricted ($10.2 million out of $18.7 million), limiting available liquidity for ongoing operations and potentially constraining flexibility if cash burn continues at current rates.
• ●The company’s reliance on recurring customer revenue for three-quarters of total revenue is a strength, but any slowdown in customer retention or chronic medication demand could quickly impact top-line growth and margin improvement.

Bottom line

TelyRx delivered strong revenue growth and improved gross margins in Q3 2026, but this came alongside widening operating losses and sharply negative free cash flow. The company’s strategy of investing heavily in marketing, infrastructure, and a major capacity expansion has yet to yield a path to profitability, and most of its cash is restricted, reducing financial flexibility. While recurring revenue growth and a 17% increase in revenue per visitor are positives, the lack of detail on the Clearwater expansion’s expected impact and the continued acceleration of losses are red flags. Investors should focus on whether the company can translate top-line momentum into narrowing losses and sustainable cash generation in coming quarters. The most important takeaway is that revenue growth alone is not yet delivering financial sustainability, and the company must demonstrate that its investments can reverse the trend of rising losses.

Announcement summary

(TSX:TELY) (OTCQX:TELYF) TelyRx Holdings Inc. announced financial results for the third quarter ended September 30, 2026. Revenue for Q3 2026 was $23.1 million, up from $12.3 million in Q3 2025, representing an increase of $10.8 million or 88%. Net loss from operations was $2.7 million, compared to $0.9 million in Q3 2025. Adjusted EBITDA loss was $1.3 million, compared to $0.4 million in Q3 2025. Gross profit for Q3 2026 was $13.8 million, with a gross profit margin of 60%, compared to $6.9 million and a margin of 56% in Q3 2025. Revenue from recurring customers was $17.4 million in the quarter, up 12% from last quarter, and now makes up three quarters of total revenue. Revenue from new customers was $5.7 million. Cost of revenue was $9.3 million for Q3 2026, compared to $5.5 million for Q3 2025. Cash and cash equivalents including restricted cash were $18,677,000 at September 30, 2026, compared to $1,790,000 at September 30, 2025. Of this, $10,200,000 was restricted cash held as collateral for the company's credit facility ($1,004,000 current, $9,196,000 non-current). The company launched the new TelyRx brand and website, resulting in a 17% improvement in revenue per visitor. The formulary was increased to more than 500 everyday medications. The company announced expansion of operations in Clearwater, Florida, which will more than triple capacity at the Clearwater location. Loss from operations increased due primarily to $1.0 million of non-cash stock-based compensation, increased advertising and marketing investment, and higher general and operating expenses to expand infrastructure, personnel, and operational capabilities. For the nine months ended September 30, 2026, net cash and cash equivalents used in operating activities was $7,902,000, and purchase of property, equipment, and intangible assets was $1,460,000, resulting in Free Cash Flow of negative $9,362,000. For the nine months ended September 30, 2025, net cash and cash equivalents used in operating activities was $271,000, and purchase of property, equipment, and intangible assets was $1,178,000, resulting in Free Cash Flow of negative $1,449,000. The company will host a conference call to discuss its third quarter 2026 financial results on Friday, November 6, 2026, at 8:30 a.m. Eastern Time. Vanessa Slowey is President and Chief Executive Officer of TelyRx.

Disagree with this article?